- Arthropod-borne viral infections testing, which involves diagnostic tools to detect viruses transmitted by vectors such as mosquitoes and ticks, is becoming an essential component of global infectious disease management, particularly in endemic and emerging regions, due to its critical role in timely outbreak response and public health preparedness
- The escalating demand for testing solutions is primarily fueled by rising global temperatures and urbanization, which are expanding vector habitats, along with the increasing frequency of arboviral outbreaks such as Dengue, Zika, and Chikungunya, prompting the need for rapid and reliable diagnostic methods
- Asia-Pacific dominated the arthropod-borne viral infections testing market with the largest revenue share of 36.9% in 2024, driven by a high prevalence of mosquito-borne diseases, expanding healthcare infrastructure, and strong governmental initiatives for disease surveillance, with India emerging as the leading country due to its large population base and increasing investments in diagnostic capacity
- Middle East and Africa is expected to be the fastest growing region in the market during the forecast period, supported by improving healthcare access, rising awareness of vector-borne disease risks, and growing investments in public health diagnostics, particularly in South Africa, Egypt, and Saudi Arabia
- Immunoassays segment dominated the arthropod-borne viral infections testing market with a market share of 44.6% in 2024, driven by its high sensitivity, rapid turnaround time, and widespread availability for detecting a broad range of arboviral pathogens
